VELESSIA Trademark

Trademark Overview


On Thursday, February 18, 2021, a trademark application was filed for VELESSIA with the United States Patent and Trademark Office. The USPTO has given the VELESSIA trademark a serial number of 90533576. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, July 3, 2023. This trademark is owned by Allergan Sales, LLC. The VELESSIA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; hormone replacement therapy preparations; pharmaceutical preparations for the prevention of preterm birth or pregnancy; pharmaceutical preparations...
velessia

General Information


Serial Number90533576
Word MarkVELESSIA
Filing DateThursday, February 18, 2021
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, July 3, 2023
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 5, 2022

Trademark Statements


Goods and ServicesPharmaceutical preparations used in connection with anti-aging, namely, for use in the treatment of glabellar lines, facial wrinkles, asymmetries and defects and conditions of the human skin, and for facial aesthetic surgery, facial aesthetic reconstruction, and breast aesthetic treatment procedures; topical antibiotics, anti-inflammatory, anti-infective, anti-glaucoma agents and decongestant formulations; sterile antibiotic ointments; ocular contact lens wetting solutions, artificial tears and pharmaceutical preparations for the treatment of minor ocular inflammations and allergic conditions; dermatological formulations, namely, medicated dry skin lotions and creams, acne medications and medicated skin lightener lotions and creams; oral, transdermal, injectable and intravaginal contraceptive preparations; intravaginal contraceptive sponge; hormone replacement therapy preparations; pharmaceutical preparations for the prevention of preterm birth or pregnancy; pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; pharmaceutical preparations for the treatment and prevention of osteoporosis; pharmaceutical preparations for the treatment and prevention of endometriosis; pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; iron chelating pharmaceutical preparations; fertility enhancing pharmaceutical preparations; pharmaceutical preparations and medicines for the treatment and prevention of sexual dysfunction; pharmaceutical preparations and medicines for the treatment of sensory organ disorders; pharmaceutical preparations and medicines for the treatment of central nervous system disorders; pharmaceutical preparations and medicines for the treatment of urogenital organ disorders; pharmaceutical preparations and medicines for the treatment of circulatory system disorders; pharmaceutical preparations and medicines for the treatment of cardiovascular and blood pressure; pharmaceutical preparations for the treatment and prevention of digestive tract, gastrointestinal and dermatological diseases and disorders; pharmaceutical preparations and medicines for the treatment and prevention of irritable bowel syndrome; pharmaceutical preparations that support, encourage or promote bone strength or bone health or which are used in the treatment of bone disorders or bone diseases; antibiotics; antifungal preparations; antivirals and antiprotozoals; pharmaceutical preparations for the prevention and treatment of bacterial infections; pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; pharmaceutical preparations for the prevention and treatment of neurological diseases and disorders; pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of hypertension; preparations for the prevention and treatment of Alzheimer's disease, dementia, aids-related dementia, CNS, neurological disorders, neurodegenerative disorders, and depression; neuroprotective agent; antidepressants; pharmaceutical preparations, namely, antipsychotics; coronary vasodilating agents; pharmaceutical preparations for the treatment of hypothyroidism; pharmaceutical and cosmeceutical preparations for skin care, namely, medicated skin cleansers, toners, moisturizers, rejuvenators, rehydrating creams, and lotions for the face and body

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, May 19, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAllergan Sales, LLC
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressIrvine, CA 92612

Party NameAllergan Sales, LLC
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressIrvine, CA 92612

Trademark Events


Event DateEvent Description
Monday, July 3, 2023ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, July 3, 2023ABANDONMENT - NO USE STATEMENT FILED
Wednesday, November 30, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, November 28, 2022SOU EXTENSION 1 GRANTED
Monday, November 28, 2022SOU EXTENSION 1 FILED
Monday, November 28, 2022TEAS EXTENSION RECEIVED
Tuesday, May 31, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, April 5, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 5, 2022PUBLISHED FOR OPPOSITION
Wednesday, March 16, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, March 3, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 2, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 2, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, March 2, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, September 16, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, September 16, 2021NON-FINAL ACTION E-MAILED
Thursday, September 16, 2021NON-FINAL ACTION WRITTEN
Tuesday, September 14, 2021ASSIGNED TO EXAMINER
Wednesday, May 19, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, February 22, 2021NEW APPLICATION ENTERED